An artificial blood-brain barrier model that has been constructed by researchers at Uppsala University is quick and accurate, and it may be used to assess how well antibody-based treatments can reach the brain. The new model may lessen the requirement for animal testing, which is now the mos
New Delhi [India], February 23 (ANI/PNN): KnowDis and IIT Delhi's Yardi School of Artificial Intelligence are collaborating to develop cutting-edge Artificial Intelligence models that can discover potential antibodies for treating various kinds of diseases. The collaboration involves two ren
There is currently no medication available to treat non-alcoholic liver disease, which affects many type 2 diabetes patients and can develop into more serious liver ailments. A therapeutic option for the treatment of fatty liver has been identified in a study led by Karolinska Institute rese
There is presently no medication available to treat non-alcoholic fatty liver disease, which affects many patients with type 2 diabetes and can lead to other serious liver illnesses. A therapeutic candidate for the treatment of fatty liver has been identified in a study headed by Karolinska
Before World Cancer Day (4 February), a new study from the University of Southampton's Centre for Cancer Immunology demonstrated that altering how tightly an antibody attaches to a target could enhance cancer therapies.
A method for finding high-affinity antibody therapeutics that is based on artificial intelligence (AI) has been created by researchers at the University of California San Diego School of Medicine.
The most recent study clarifies how Pfizer and Moderna mRNA boosters influence the persistence of our Covid-19 antibodies. According to the researchers, a booster produced more durable antibodies in all individuals, including those who had recovered from a Covid-19 infection.
New research from the University of Virginia School of Medicine speaks to the benefits of a Covid-19 booster. The new findings shed light on how mRNA boosters - both Pfizer and Moderna - affect the durability of our antibodies to Covid-19. A booster, the researchers report, made for longer-l
According to a study, patients with thyroid eye disease treated with the minimally invasive insulin-like growth factor I blocking antibody teprotumumab saw improvements in their symptoms, appearance, and quality of life.
Patients with thyroid eye disease who used the minimally invasive insulin-like growth factor I blocking antibody, teprotumumab, experienced improvement in their symptoms, appearance and quality of life, according to a study recently published in the New England Journal of Medicine.
Nearly three years into the pandemic, many of us now carry antibodies against the virus--due to an infection or two, a few doses of mRNA vaccine, or a round of monoclonal-antibody treatment. But not all immune responses are created equal, and how we first developed our antibodies may influen
The treatment, which is referred to as a "bispecific antibody," binds to both T cells and multiple myeloma cells and instructs the T cells, which are white blood cells that can be used to fight off diseases